Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to Ja...
Gespeichert in:
| Veröffentlicht in: | International journal of general medicine 2021-01, Vol.14, p.9153-9161 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9161 |
|---|---|
| container_issue | |
| container_start_page | 9153 |
| container_title | International journal of general medicine |
| container_volume | 14 |
| creator | Diao, Wei-Ying Ding, Cheng-Long Yuan, Bo-Yang Li, Zan Sun, Na Huang, Jia-Bin |
| description | Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.
Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.
Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P |
| doi_str_mv | 10.2147/IJGM.S328908 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2610730729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687382814</galeid><doaj_id>oai_doaj_org_article_a5d049127c6d4492b1eadf25a058b1bd</doaj_id><sourcerecordid>A687382814</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-7548a745f6164f8730ee335c1d9b16a190e617a60763fbc807a7471e0ee6b9283</originalsourceid><addsrcrecordid>eNqNktGL0zAcx4so3nn65rMEBBF0M0nTJH0RjnLuJlOHp88hTdMto0t2Setx_72_uTk38UEKbUg_v2_y_fLNsucEjylh4t304-TT-CanssTyQXZOiJAjgQV7eLQ-y56ktMKYc07yx9lZzqTEvGDnmas6553RHaqWOmrT2-hS70xC2jdoHsPCh-QSCi26vvpK0cR6i-ZL60N_v7HIeTTXvbO-T-jO9Uv0OfjRzVp3oGfhNRv8AlXaGxufZo9a3SX7bP-9yL5_uPpWXY9mXybT6nI2MoXg_UgUTGrBipYTzlopcmxtnheGNGVNuCYltpwIzbHgeVsbiQXQgljAeF1SmV9k051uE_RKbaJb63ivgnbq10aIC6UjOOys0kWDWUmoMLxhrKQ1sbppaaFxIWtSN6D1fqe1Geq1bQz4jLo7ET39491SLcIPJTnjhFAQeL0XiOF2sKlXa5cMJKO9DUNSlNMcg4ciB_TlX-gqDNFDVEARDEEIWv6hFhoMON8GONdsRdUlh7QklYQBNf4HBU9j184Eb1sH-ycDr44GllZ3_TKFbuhd8OkUfLsDTQwpRdsewiBYbfuotn1U-z4C_uI4wAP8u4AAyB1wZ-vQJgNVMvaAYQymuSgpgxWmlev19kZVGHwPo2_-fzT_CbT19_c</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610730729</pqid></control><display><type>article</type><title>Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer</title><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Diao, Wei-Ying ; Ding, Cheng-Long ; Yuan, Bo-Yang ; Li, Zan ; Sun, Na ; Huang, Jia-Bin</creator><creatorcontrib>Diao, Wei-Ying ; Ding, Cheng-Long ; Yuan, Bo-Yang ; Li, Zan ; Sun, Na ; Huang, Jia-Bin</creatorcontrib><description>Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.
Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.
Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P<0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P<0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P 0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P<0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P<0.05).
Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB similar to IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.</description><identifier>ISSN: 1178-7074</identifier><identifier>EISSN: 1178-7074</identifier><identifier>DOI: 10.2147/IJGM.S328908</identifier><identifier>PMID: 34880654</identifier><language>eng</language><publisher>ALBANY: Dove Medical Press Ltd</publisher><subject>afatinib ; Cancer ; Cancer therapies ; Carboplatin ; Chemotherapy ; ct signs ; Development and progression ; Drug dosages ; Gene amplification ; Gene expression ; Gene mutations ; General & Internal Medicine ; Genes ; Genetic aspects ; Genetic screening ; Genotype & phenotype ; her2 genotype ; Hospitals ; Life Sciences & Biomedicine ; Lung cancer ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Medical prognosis ; Medicine, General & Internal ; Mutation ; non-small cell lung cancer ; Original Research ; Patients ; Pemetrexed ; Prognosis ; Radiation therapy ; Science & Technology ; Signal transduction ; Tumors</subject><ispartof>International journal of general medicine, 2021-01, Vol.14, p.9153-9161</ispartof><rights>2021 Diao et al.</rights><rights>COPYRIGHT 2021 Dove Medical Press Limited</rights><rights>2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Diao et al. 2021 Diao et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>3</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000726792400002</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c576t-7548a745f6164f8730ee335c1d9b16a190e617a60763fbc807a7471e0ee6b9283</citedby><cites>FETCH-LOGICAL-c576t-7548a745f6164f8730ee335c1d9b16a190e617a60763fbc807a7471e0ee6b9283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646112/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646112/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,3863,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34880654$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diao, Wei-Ying</creatorcontrib><creatorcontrib>Ding, Cheng-Long</creatorcontrib><creatorcontrib>Yuan, Bo-Yang</creatorcontrib><creatorcontrib>Li, Zan</creatorcontrib><creatorcontrib>Sun, Na</creatorcontrib><creatorcontrib>Huang, Jia-Bin</creatorcontrib><title>Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer</title><title>International journal of general medicine</title><addtitle>INT J GEN MED</addtitle><addtitle>Int J Gen Med</addtitle><description>Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.
Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.
Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P<0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P<0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P 0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P<0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P<0.05).
Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB similar to IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.</description><subject>afatinib</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carboplatin</subject><subject>Chemotherapy</subject><subject>ct signs</subject><subject>Development and progression</subject><subject>Drug dosages</subject><subject>Gene amplification</subject><subject>Gene expression</subject><subject>Gene mutations</subject><subject>General & Internal Medicine</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic screening</subject><subject>Genotype & phenotype</subject><subject>her2 genotype</subject><subject>Hospitals</subject><subject>Life Sciences & Biomedicine</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Medical prognosis</subject><subject>Medicine, General & Internal</subject><subject>Mutation</subject><subject>non-small cell lung cancer</subject><subject>Original Research</subject><subject>Patients</subject><subject>Pemetrexed</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Science & Technology</subject><subject>Signal transduction</subject><subject>Tumors</subject><issn>1178-7074</issn><issn>1178-7074</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>DOA</sourceid><recordid>eNqNktGL0zAcx4so3nn65rMEBBF0M0nTJH0RjnLuJlOHp88hTdMto0t2Setx_72_uTk38UEKbUg_v2_y_fLNsucEjylh4t304-TT-CanssTyQXZOiJAjgQV7eLQ-y56ktMKYc07yx9lZzqTEvGDnmas6553RHaqWOmrT2-hS70xC2jdoHsPCh-QSCi26vvpK0cR6i-ZL60N_v7HIeTTXvbO-T-jO9Uv0OfjRzVp3oGfhNRv8AlXaGxufZo9a3SX7bP-9yL5_uPpWXY9mXybT6nI2MoXg_UgUTGrBipYTzlopcmxtnheGNGVNuCYltpwIzbHgeVsbiQXQgljAeF1SmV9k051uE_RKbaJb63ivgnbq10aIC6UjOOys0kWDWUmoMLxhrKQ1sbppaaFxIWtSN6D1fqe1Geq1bQz4jLo7ET39491SLcIPJTnjhFAQeL0XiOF2sKlXa5cMJKO9DUNSlNMcg4ciB_TlX-gqDNFDVEARDEEIWv6hFhoMON8GONdsRdUlh7QklYQBNf4HBU9j184Eb1sH-ycDr44GllZ3_TKFbuhd8OkUfLsDTQwpRdsewiBYbfuotn1U-z4C_uI4wAP8u4AAyB1wZ-vQJgNVMvaAYQymuSgpgxWmlev19kZVGHwPo2_-fzT_CbT19_c</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Diao, Wei-Ying</creator><creator>Ding, Cheng-Long</creator><creator>Yuan, Bo-Yang</creator><creator>Li, Zan</creator><creator>Sun, Na</creator><creator>Huang, Jia-Bin</creator><general>Dove Medical Press Ltd</general><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210101</creationdate><title>Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer</title><author>Diao, Wei-Ying ; Ding, Cheng-Long ; Yuan, Bo-Yang ; Li, Zan ; Sun, Na ; Huang, Jia-Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-7548a745f6164f8730ee335c1d9b16a190e617a60763fbc807a7471e0ee6b9283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>afatinib</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carboplatin</topic><topic>Chemotherapy</topic><topic>ct signs</topic><topic>Development and progression</topic><topic>Drug dosages</topic><topic>Gene amplification</topic><topic>Gene expression</topic><topic>Gene mutations</topic><topic>General & Internal Medicine</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic screening</topic><topic>Genotype & phenotype</topic><topic>her2 genotype</topic><topic>Hospitals</topic><topic>Life Sciences & Biomedicine</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Medical prognosis</topic><topic>Medicine, General & Internal</topic><topic>Mutation</topic><topic>non-small cell lung cancer</topic><topic>Original Research</topic><topic>Patients</topic><topic>Pemetrexed</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Science & Technology</topic><topic>Signal transduction</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diao, Wei-Ying</creatorcontrib><creatorcontrib>Ding, Cheng-Long</creatorcontrib><creatorcontrib>Yuan, Bo-Yang</creatorcontrib><creatorcontrib>Li, Zan</creatorcontrib><creatorcontrib>Sun, Na</creatorcontrib><creatorcontrib>Huang, Jia-Bin</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of general medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diao, Wei-Ying</au><au>Ding, Cheng-Long</au><au>Yuan, Bo-Yang</au><au>Li, Zan</au><au>Sun, Na</au><au>Huang, Jia-Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer</atitle><jtitle>International journal of general medicine</jtitle><stitle>INT J GEN MED</stitle><addtitle>Int J Gen Med</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>14</volume><spage>9153</spage><epage>9161</epage><pages>9153-9161</pages><issn>1178-7074</issn><eissn>1178-7074</eissn><abstract>Introduction: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients.
Methods: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to January 2018 were retrospectively analyzed. The clinicopathological information, CT signs, clinical efficacy and long-term prognosis were collected and compared.
Results: A total of 249 NSCLC patients underwent HER2 gene testing, 21 of them (8.43%) complied with HER2 alterations [HER2 (+)], and there were significant differences in tumor stages among patients with different HER2 phenotypes (P<0.05). Among 21 NSCLC patients with HER2 (+), HER2 gene mutation was found in 17 patients (81%), and HER2 gene amplification in 4 patients (19%). Among the HER2 mutations, 12 cases (57%) were 20 exon mutations, and 5 cases (19%) were other mutations. Analysis of CT signs showed that border lobulation/burr, necrosis sign and pleural depression were correlated with HER2 gene mutation (P<0.05). The incidence of EGRF mutation in HER (+) patients was significantly lower than that in HER (-) patients (P 0.05), but there was no significant difference in the incidence of ALK gene mutation among different HER phenotypes (P 0.05). The disease control rate of HER2 (+) patients was significantly lower than that of HER2 (-) patients, and the 12-month progression-free survival rate and survival rate of HER2 (+) patients were significantly higher than those of HER2 (-) patients (P<0.05). There was no significant difference in the incidence of ADR among HER2 patients with different phenotypes, but the incidence of ADR (adverse drug reaction) in HER2 (+) patients with Grade 3 or 4 was significantly higher than that in the control group (P<0.05).
Discussion: The incidence of HER2 gene mutations in NSCLC patients is relatively low, but it is far commoner in patients with stage IIIB similar to IV, among which exon 20 mutations are the most prevalent. In CT signs, the lesion lobulated sign/spiculated sign, necrosis signs, and pleural depression signs are related to HER2 gene mutations. In addition, HER2 gene mutations play a crucial role in the clinical prognosis and treatment safety of patients.</abstract><cop>ALBANY</cop><pub>Dove Medical Press Ltd</pub><pmid>34880654</pmid><doi>10.2147/IJGM.S328908</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-7074 |
| ispartof | International journal of general medicine, 2021-01, Vol.14, p.9153-9161 |
| issn | 1178-7074 1178-7074 |
| language | eng |
| recordid | cdi_proquest_journals_2610730729 |
| source | DOAJ Directory of Open Access Journals; Dove Press Free; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | afatinib Cancer Cancer therapies Carboplatin Chemotherapy ct signs Development and progression Drug dosages Gene amplification Gene expression Gene mutations General & Internal Medicine Genes Genetic aspects Genetic screening Genotype & phenotype her2 genotype Hospitals Life Sciences & Biomedicine Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Medical prognosis Medicine, General & Internal Mutation non-small cell lung cancer Original Research Patients Pemetrexed Prognosis Radiation therapy Science & Technology Signal transduction Tumors |
| title | Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T16%3A04%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Characteristics%20and%20Prognosis%20of%20HER2%20Gene%20Phenotype%20in%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer&rft.jtitle=International%20journal%20of%20general%20medicine&rft.au=Diao,%20Wei-Ying&rft.date=2021-01-01&rft.volume=14&rft.spage=9153&rft.epage=9161&rft.pages=9153-9161&rft.issn=1178-7074&rft.eissn=1178-7074&rft_id=info:doi/10.2147/IJGM.S328908&rft_dat=%3Cgale_proqu%3EA687382814%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610730729&rft_id=info:pmid/34880654&rft_galeid=A687382814&rft_doaj_id=oai_doaj_org_article_a5d049127c6d4492b1eadf25a058b1bd&rfr_iscdi=true |